{"ticker": {"uuid": "8731af34-b605-4b09-97b8-7266786ebaa0", "symbol": "ALLO", "name": "Allogene Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors", "summary": "Allogene Therapeutics announced the publication of complete Phase 1 data for its investigational therapy ALLO-316 in the Journal of Clinical Oncology, showing durable remissions in metastatic solid tumors. The TRAVERSE study, conducted in collaboration with The University of Texa", "url": "https://www.manilatimes.net/2026/07/15/tmt-newswire/globenewswire/allogene-therapeutics-announces-journal-of-clinical-oncology-publication-of-phase-1-results-of-allo-316-highlighting-first-durable-remissions-following-allogeneic-car-t-for-treatment-of-metastatic-solid-tumors/2385064", "source_name": "The Manila Times", "published_at": "2026-07-15T12:38:18", "published_display": "15 Jul 2026 12:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO) Q3 2024 earnings summary", "summary": "Allogene Therapeutics released its Q3 2024 earnings summary, highlighting the advancement of its key trials, including the pivotal Phase 2 ALPHA3 trial for cema-cel, with enrollment expected to complete in H1 2026. The company reported $403.4 million in cash, cash equivalents, an", "url": "https://quartr.com/events/allogene-therapeutics-allo-q3-2024_ozAJGz96", "source_name": "Quartr", "published_at": "2026-07-14T00:11:14", "published_display": "14 Jul 2026 00:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Allogene Therapeutics (ALLO) Proxy filing Summary", "summary": "Allogene Therapeutics (ALLO) issued a proxy filing summary on May 21, 2026, correcting total compensation figures for Dr. Chang (2024), Dr. Roberts (2025), and Mr. Parker (2025) in their Summary Compensation Table, with no other changes to the proxy statement or proposals for the", "url": "https://quartr.com/events/allogene-therapeutics-allo-proxy-filing_ozAJLWML", "source_name": "Quartr", "published_at": "2026-07-13T09:40:45", "published_display": "13 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Sinks 13%: Here\u2019s Why", "summary": "", "url": "https://finance.yahoo.com/m/57b629c0-9b57-300d-bab5-69e9c31cc364/kyverna-therapeutics-sinks.html", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T19:59:59+00:00", "published_display": "10 Jul 2026 19:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer cell therapy pioneer Allogene\u2019s new CEO is talking about a new revolution", "summary": "Zach Roberts, the new CEO of Allogene Therapeutics Inc., is advocating for a revolutionary approach to cancer cell therapy. He aims to champion new methods to address this deadly disease. The article describes Roberts' vision for the future of cancer treatment at Allogene.", "url": "https://www.bizjournals.com/sanfrancisco/news/2026/07/09/cancer-cell-therapy-lymphoma-allogene-new-ceo-lbcl.html", "source_name": "The Business Journals", "published_at": "2026-07-09T13:54:00", "published_display": "09 Jul 2026 13:54", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO) CEO granted 476,190 options and 134,530 RSUs", "summary": "Allogene Therapeutics President and CEO Zachary Roberts was granted 476,190 stock options with an exercise price of $2.11 per share and 134,530 Restricted Stock Units (RSUs). These equity awards are compensation-related and not open-market transactions. The stock options vest ove", "url": "https://www.stocktitan.net/sec-filings/ALLO/form-4-allogene-therapeutics-inc-insider-trading-activity-beb88dc09e60.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:51:49", "published_display": "06 Jul 2026 21:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPR2tMOFk1SXg4Uk9sM2VwT082eDEzRHd4TnNhN2Nsa0hXeGliQlZfQnRwTGhITnlWVjdVVEFDRHdyUFNWanVpOGExVEprQktoWXVJUVI0amVjaW9TWWZyYVp1Y3pydUhaZDZVTWhzQ3pIMnc5NkVuZk5SXzEtTkd5OEY1Q3NoRHNqTVR2YlQ0THk1T2lKaGY4ZUhZX212YmhpamNr?oc=5", "source_name": "Market source", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics: High-Upside Bet On The Next Wave Of CAR-T Innovation (NASDAQ:ALLO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQRWdjTGd2UjZkMmF1UFBxdXpPV2V3RG1sOTJGTWNMbzZyREl5Skh1QjJQWVluZWJCNi1YZmVPLTVDVm5JLVp6SkpQNS04Y1JEMWVRdi01SGVXTjBKUjVWbzJxWkZ6ZXhscDNOVmJsMUFkWFd0QzlpSGhQTkI0OVJfTjBXVGttYklzOTlFZ1Bid2J6U0ZwZy1SYUFEZ0pBNDlidXdmNWxOaHdRMktwc1lBNW96bEdoRWhE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. \u2013 NASDAQ:ALLO", "summary": "The article focuses on the enterprise value to EBITDA forward for Allogene Therapeutics, Inc. (NASDAQ:ALLO). It appears to be a stub or a data point from a financial platform like TradingView, indicating that specific financial metrics are available for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-ALLO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T07:10:13", "published_display": "28 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Allogene Therapeutics, Inc. \u2013 NASDAQ:ALLO", "summary": "This page provides financial information for Allogene Therapeutics, Inc. (NASDAQ: ALLO), focusing on its Price to Earnings Forward metric. The content highlights the company's stock market data and emphasizes that specific financial values for this metric are presented within the", "url": "https://www.tradingview.com/symbols/NASDAQ-ALLO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:09:47", "published_display": "27 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Allogene Therapeutics, Inc. \u2013 BOATS:ALLO", "summary": "This article provides financial information for Allogene Therapeutics, Inc. (ALLO), specifically focusing on its enterprise value to revenue forward. The data is presented within the context of the Blue Ocean Alternative Trade System (BOATS) on the TradingView platform.", "url": "https://www.tradingview.com/symbols/BOATS-ALLO/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:09:47", "published_display": "27 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Allogene Therapeutics, Inc. \u2013 BOATS:ALLO", "summary": "This article provides the \"Price to sales forward\" metric for Allogene Therapeutics, Inc. (ALLO), listed on the Blue Ocean Alternative Trade System (BOATS). It notes the market is currently closed with no trades. The content is primarily a data point surrounded by navigation and ", "url": "https://www.tradingview.com/symbols/BOATS-ALLO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T13:10:50", "published_display": "27 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPRmt6OVM2UnZfM0YwTWJaSWNiWDBaRXVyZXF3ZTY5ck5OQW9fcFhTOEY3YUVuNzY4LVNtS19DZzA5LW1yblMzdVNEc29YZUpsRnFPQXQtczZkYnZYTm1vbW1LelRJdzlJc3hqbWRHM0NpQS1WOExRNlpDQld3ME1JVEROZzJaX0I2Sm5kdEprZjM5ZVJBMHNZWVF3M0ZCWXJxYTJpcg?oc=5", "source_name": "Market source", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene (ALLO) director Owen Witte awarded 95,400 RSUs with deferred delivery", "summary": "Allogene Therapeutics director Owen N. Witte was granted 95,400 Restricted Stock Units (RSUs), which vest in two equal semi-annual installments over one year. Witte has elected to defer the receipt of the underlying common stock until 30 days after his continuous service terminat", "url": "https://www.stocktitan.net/sec-filings/ALLO/form-4-allogene-therapeutics-inc-insider-trading-activity-deefae0eba88.html", "source_name": "Stock Titan", "published_at": "2026-06-26T11:12:25", "published_display": "26 Jun 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLO)", "summary": "This article provides an overview of Allogene Therapeutics, Inc. (NASDAQ: ALLO) financials, stock performance, and analyst forecasts. It includes key figures such as the current stock price, market capitalization, earnings per share, and revenue, alongside analysts' high and low ", "url": "https://www.tradingview.com/symbols/NASDAQ-ALLO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:35", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALLO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Allogene Therapeutics, Inc. (ALLO) stock analysis, including its current price, analyst price targets, and future predictions. It details the company's financial performance, market capitalization, earnings reports, and employee count, alongsi", "url": "https://www.tradingview.com/symbols/NASDAQ-ALLO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:09:31", "published_display": "25 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recent pharma exec shake-ups signal strategic shifts", "summary": "Recent executive movements at major pharmaceutical companies like Novo Nordisk, Genentech, and Allogene reflect strategic adjustments within the industry. Novo Nordisk saw a significant M&A executive depart, while Genentech underwent leadership layoffs due to pipeline restructuri", "url": "https://www.pharmavoice.com/news/pharma-executive-changes-novo-genentech-allogene/823548/", "source_name": "Pharma Voice", "published_at": "2026-06-24T13:10:15", "published_display": "24 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (NASDAQ: ALLO) grants director 95,400 RSUs", "summary": "Allogene Therapeutics director Deborah M. Messemer was granted 95,400 restricted stock units (RSUs) as reported in a Form 4 SEC filing. These RSUs, which carry no purchase price, give her the contingent right to receive 95,400 shares of Allogene common stock upon vesting. The ves", "url": "https://www.stocktitan.net/sec-filings/ALLO/form-4-allogene-therapeutics-inc-insider-trading-activity-a710413f0e9d.html", "source_name": "Stock Titan", "published_at": "2026-06-24T07:39:38", "published_display": "24 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Allogene Therapeutics Inc For: 23 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Allogene Therapeutics Inc. as of June 23. It includes the company's stock symbol ALLO and its current price performance, noting a -1.43% change. The content primarily states the filing without providing further detail", "url": "https://ca.investing.com/news/stock-market-news/form-4-allogene-therapeutics-inc-for-23-june-93CH-4704102", "source_name": "Investing.com Canada", "published_at": "2026-06-23T21:09:44", "published_display": "23 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO) director receives 95,400 RSU equity award", "summary": "Allogene Therapeutics director Vicki L. Sato was granted 95,400 Restricted Stock Units (RSUs) as part of her compensation. These RSUs will vest in two equal semi-annual installments over one year, contingent on her continued service. The filing, a Form 4, indicates this is an equ", "url": "https://www.stocktitan.net/sec-filings/ALLO/form-4-allogene-therapeutics-inc-insider-trading-activity-85fe8c84bccc.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:10:15", "published_display": "23 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO) director receives 144,400 stock options grant", "summary": "Allogene Therapeutics director Stephen Mayo was granted 144,400 stock options with an exercise price of $2.00 per share. These options vest in 12 equal monthly installments and expire on June 18, 2036. Following this grant, Mayo holds options for 144,400 shares of Allogene common", "url": "https://www.stocktitan.net/sec-filings/ALLO/form-4-allogene-therapeutics-inc-insider-trading-activity-1580c42003f8.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:09:44", "published_display": "23 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene (ALLO) director awarded 95,400 RSUs with deferred share delivery", "summary": "Allogene Therapeutics, Inc. (ALLO) director Elizabeth A. Barrett was granted 95,400 Restricted Stock Units (RSUs) as part of her compensation. These RSUs will vest in two semi-annual installments over one year, contingent on her continued service. Barrett has opted to defer the d", "url": "https://www.stocktitan.net/sec-filings/ALLO/form-4-allogene-therapeutics-inc-insider-trading-activity-d570cccbe8bd.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:09:44", "published_display": "23 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (NASDAQ: ALLO) doubles authorized shares and files $135M ATM plan", "summary": "Allogene Therapeutics (NASDAQ: ALLO) announced that its stockholders approved an increase in authorized common shares from 400 million to 800 million at the 2026 Annual Meeting. This change, effective June 18, 2026, provides the company with greater flexibility for future equity ", "url": "https://www.stocktitan.net/sec-filings/ALLO/8-k-allogene-therapeutics-inc-reports-material-event-46bcdc550f33.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:40:13", "published_display": "22 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Allogene Therapeutics Inc For: 22 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPSkV2bVBsVDJVaUZtX1BNTUpLNExtNFV1UlFxcDJyVlBFalpMalpOSG02SHhkVzZwUkxTWHpsQVExZFRZVmY4TmJBdkZCYjBwVGxVdC1rQzZJUHI2WTI1SEhPQW81anBmNEl0Z0NOVjQ0QzNld29rUnM3YlVpTXZLdk9sX1JUMW1tS1c5WmQ1YWl3MFR3UlN5T0YzMTFxT0x3NVE1UWMtb1h5d3c4UGc?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALLO: All proposals, including director elections and share increase, were approved without contest", "summary": "Allogene Therapeutics, Inc. (ALLO) held its 2026 AGM where all five key proposals were approved unanimously. These proposals included director elections, executive compensation, annual advisory votes, an increase in authorized shares, and auditor ratification. No questions were r", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3620571:0-allo-all-proposals-including-director-elections-and-share-increase-were-approved-without-contest/", "source_name": "TradingView", "published_at": "2026-06-18T15:40:54", "published_display": "18 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics Inc (ALLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Allogene Therapeutics Inc (ALLO), including business segments, regional revenue, and profit contribution. However, the core information indicates that the relevant financial data has not yet been disclosed b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-allo/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T18:39:02", "published_display": "17 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNUUE4T1NFN2F6QS1FYmRDbl9YSWNYUU9jby1scGVKWHB6STVKNm1vakZ4RFRGZWxldGR0eGtKSVlaeURUZWZzZDVhMnpGM1NBNThrSU80WVR4UzBTNFl3WTdkLVRNcHhoQkt0TDRQUUg5UENEeFRPVEhGVlpDRzVhNDFlSnAxU0xHeGtWNlpQcUU5TjYzTWJDZlY4LVIxS2RscTdB?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Small Cap Stocks with Potential to Rise 1000 Percent", "summary": "This article highlights small-cap stocks with significant growth potential, focusing on Allogene Therapeutics, Inc. (NASDAQ:ALLO) as a key example. Allogene is a clinical-stage biotechnology company developing CAR T cell therapies for cancer and autoimmune diseases, with importan", "url": "https://www.insidermonkey.com/blog/10-small-cap-stocks-with-potential-to-rise-1000-percent-1782072/3/", "source_name": "Insider Monkey", "published_at": "2026-06-16T14:09:19", "published_display": "16 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPTjI2VXQ0ZG0yNGQ5RW02R0tiWjJLaE1NWWFBdTd4NUdSSm9fNXN2ZEh2WUZYRTF4eFdNVzh5U0doal9zYXQ3REtqSkFuSE5mbjEtUDI4Z2tDWlI2cTdwZExLVGY0TXZrNnFoMGdzUzhYUjBRVE83Ny1zdDRlYmdHdENaVDlfX1d3aGExb3BhU1Buc1IwVlpXTE1OakEyVHhlQmh3RFoxbw?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAR T-Cell Therapy for Non-Hodgkin\u2019s lymphoma Market Emerging as a High-Growth Healthcare Investment Space Through 2036 \u2013 DelveInsight | Gilead Sciences, Kite Pharma, Novartis, BMS, Allogene Therapeut", "summary": "DelveInsight projects the CAR T-Cell Therapy for Non-Hodgkin\u2019s lymphoma market to be a high-growth healthcare investment space through 2036, driven by rising NHL prevalence and advancements in CAR T-cell therapies. The report highlights key companies like Gilead Sciences, Novarti", "url": "https://www.barchart.com/story/news/2432722/car-t-cell-therapy-for-non-hodgkins-lymphoma-market-emerging-as-a-high-growth-healthcare-investment-space-through-2036-delveinsight-gilead-sciences-kite-pharma-novartis-bms-allogene-therapeut", "source_name": "Barchart.com", "published_at": "2026-06-12T01:09:42", "published_display": "12 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio", "summary": "Allogene Therapeutics (ALLO) is highlighted as a top penny stock due to its robust CAR T-cell therapy pipeline, including positive interim results for cema-cel in the ALPHA3 trial and development of ALLO-329 for autoimmune disease. The company reported a net loss of $42.6 million", "url": "https://www.insidermonkey.com/blog/allogene-therapeutics-inc-allo-a-top-penny-stock-to-buy-on-robust-car-t-cell-portfolio-1776523/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-07T13:57:00", "published_display": "07 Jun 2026 13:57", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALLO Stock Hits 2-Year Highs \u2013 Analyst Calls Allogene\u2019s Phase 2 Trial Data To Treat Lymphoma A \u2018Home Run\u2019", "summary": "Allogene Therapeutics (ALLO) shares surged over 50% to a two-year high after interim Phase 2 trial data for Cema-Cel in treating lymphoma showed significant efficacy. The data revealed 58.3% of treated patients had no detectable disease and a 97.7% drop in cancer DNA levels, lead", "url": "https://stocktwits.com/news-articles/markets/equity/allo-stock-2year-high-biggest-intraday-gain-cancer-treatment-data/cZJ8G6sRIuK", "source_name": "Stocktwits", "published_at": "2026-06-06T22:10:09", "published_display": "06 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A pioneering founder is stepping down as CEO of his Bay Area company ahead of a major test", "summary": "David Chang, co-founder of Allogene Therapeutics Inc., is stepping down as CEO at the end of June. This leadership change occurs as the company is conducting a critical clinical trial for a potential regulatory approval of its lymphoma treatment. The San Francisco Business Times ", "url": "https://www.bizjournals.com/sanfrancisco/news/2026/06/01/cancer-lbcl-mrd-allogene-ceo-david-chang.html", "source_name": "The Business Journals", "published_at": "2026-06-01T20:40:21", "published_display": "01 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics Names Zachary Roberts as New CEO", "summary": "Allogene Therapeutics has appointed Zachary Roberts as its new President and CEO, effective July 1, 2026, succeeding co-founder David Chang. Roberts, currently EVP of R&D and Chief Medical Officer, will also join the board, bringing extensive oncology and cell therapy experience ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ALLO/pressreleases/2209878/allogene-therapeutics-names-zachary-roberts-as-new-ceo/", "source_name": "The Globe and Mail", "published_at": "2026-05-30T20:39:45", "published_display": "30 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Common Stock of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026.", "summary": "Allogene Therapeutics, Inc. has common stock subject to a lock-up agreement that ends on May 30, 2026. The lock-up period began on April 14, 2026, and prevents the company's directors and executive officers from disposing of or hedging common stock or related securities for 45 da", "url": "https://www.marketscreener.com/news/certain-common-stock-of-allogene-therapeutics-inc-are-subject-to-a-lock-up-agreement-ending-on-30-ce7f5dd8d98df223", "source_name": "www.marketscreener.com", "published_at": "2026-05-30T18:39:53", "published_display": "30 May 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics CEO David Chang Steps Down", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/allogene-therapeutics-ceo-david-chang-211802481.html", "source_name": "MT Newswires", "published_at": "2026-05-28T21:18:02+00:00", "published_display": "28 May 2026 21:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics Announces Planned CEO Succession", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/allogene-therapeutics-announces-planned-ceo-210200905.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T21:02:00+00:00", "published_display": "28 May 2026 21:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings call transcript: Allogene Therapeutics beats EPS expectations in Q1 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQMDJsTDU3c2l4ajR5SzNHWTY4NU9KdFE1OEpfSTlhaERBRmVmcWtJODFFZUtVNVoyYmVfS1lTVkI4SWlpTzlNN0pMWFpwRUJDa2ZGRl84SnpEM0tjYzRsXzNpOUo1Um9Ybm82ZFBtb2NZYVhiQkp5bmJYb3dfRkZGQTlnNHhXcnBBR2c4bmo5b002RE5VN1pZTUVFY0dUVzBNclBnd2FRNWtQUW1XaTVkblpOc0JzblBDVVZoSHZPb0JDS3hYVGZuTUUtQzh0V2R6TlE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxQNUtzQ1Y1TlZsMmtMY3NFUTN1Unh5U18xNWpYaEVhdDM4OUJibUZxQ0hjWWxTb0ZMVVVIZnRQaDRRN1d4UEhzekR5SGJLRjdNT2hXVFExdXFlRElCMEFwZnZoWFpqQVdDTXJ0bG5ZVzNmX09RaU4xUWpOVFc2VEV6Nl8yQ2pJb1hpdzEzbWt3VlRkN2JiWXFRSmFKX1JWZktOa3Z6YU05czNEaFppai1pcXNWdFhrRkxxbXpTZXdSbGt4M1kzOF9wTk1tY2lGMm5yNFB2U0xIalNvcmJleTBFWlFnM1Q5c2hzaE9HMGpYbw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (NASDAQ: ALLO) Belldegrun reports 13.47M-share stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPRjcxS09laXJiamZPYVNCaGlSZGE0UnZpdXJ3T25HbXY2a24tQXIwcG1IRkphYjhtNlRXbW9fanN4S29BUWZSem5vcGxaZXhiVVlvOW5mNzVnR1Z1YWxjSEdPMktWZjlBaGJiTzk4VVNmMVJ2amxmUlJSaXhRZVZRUjNOckVWLUw5UVRpc0Nhb3VzNFBpQ0RIZUZ4VXhzYWcycUtOam1NS2lLZlpjdXdBVElvLTFvNVdWQm9vZXFXTVBqTXNERVNJZTBNdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQQVlXblBSWWRuLTQwaEQxQ1cwUGRMTy1FYVBoMVNDN3Y2WU1XeDZoSWRtbk9qX2JaTDlIdnExcjVfUmdfbkxaU1NoaXFUSUJQNFJkQm5HTDZYbmk5MkhJTGpZb2xQbEFsdDktTDhwYllmTnY4TEdIRUtWRzZTYkEzb3lIUklxTjR0c1FmMC1aaF9xdVhSTE8wdnNZeGZEZHZaTUQxNGhLUWtPUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQeXNCNG1tM3BnMkd6NWIwQTJ1M0x6ZjJZbUpXY09tdWhUWUFWbUtjbVRxQjRsNDVMeW5xRkM5bjlhT3gwR0s3NGx6Tk01RkE2Vm4zMlB1cXcwTzJEV0VTQUNWdnFMOVE3RGZQMHNOY3hUcVBmLXVsOURHcm8ybHJaQ2N3T3QtSHdxTF94X1Z6WUYyREQ5N3FtZGFuMGRIMHpneHBKVy1B?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lymphoma trial expands to 80 sites as Allogene adds 2 countries", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPS1Jhb3VxLWVPTm83V2xQS01jY3hMbnlCck05eTJ5dmQxOUZzcUVvX05aem56X0xTZm1wblVUSDdDdmRRenFjcnFKb2EwNklwaXpablhHY1FHLW1iWVpHaGhBaV9ybjg0YkRZa1BPbHNsY0tHYThtT2xVSngwc0hkYjRTRGYybDVRRU9iOV83TnI1SlNZWmhMbzNGYUxiSVM2MkxOSEhOSU9POF9UbG9OdTgxekhDNUUyQlEyMkI2NA?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene expands lymphoma trial to South Korea, Australia", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNd3VYZktRdDRhZWZJTVlsdTVZdlY2OEgyMDNjbndmbm1qUDRYdHhpZnc5aUNSTElBU0c0c1h0bnJjWXpzZ2hQdmtXaEQ1QzNkNDFBVVZKMG0wUnI1U09fdDAwbFdvaURmX0tNclduc0FQek43NmJoQnBPUzhLTEd6LVJuWjRRSThwVmFnNlFvY3ltbmtqVGRzNTBsTWZQWUhLTVZncGM4UFpZZTIzZ2ZDZ2tfZw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Allogene sold 100.2M shares at $2, bringing in $200.4M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPS21HWEx3WEVtT2stckhaMjJtZVQ0UjNpbktENExpMEJjdXZTbEhndFlIaXVwUERaWnYxdm9LR3dZQXQwcTRoU1pLamw0TEdjRmhIdWVaT2FvMVZaVWtFWGhuQ2xITjdLUThzUzFzc3AyT1AySWdpYk1lWk5qREtvX0hiVENnNl9aMXdGNEx4SFhuaGZyYU1fVVZ3MlFPRUtCelpDWERiRGRPaS1WNWFUZE44dVZ3bTFabWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQRk4xLWxBMFJXWVN2ZTI2QnFXd1k1OTQ5aHFZajU1bEtId2N1YlNHbEs0MzlDVTVPdFBzWmUtWmtPNGw5VHJSakFBUTlQUnV0OW5Vc0k1dC14ZS1yV0pyclE5R1hoRk9yT1JMMlR2d0NiS3FBaHdUREVScWh3d3FWaGtWYWFRMlpneEdYWVBnSjBqeGFqVzJoNzdxQjZfOVFFNzAzdDVfazVXSFBVRE1mQUdB?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNWkR0cnp2X1RqTGViaU9TbnVEbW0yS3BfdkdYWVJlLXpneFA0QnJUZGptaDI0UU1keW02YXBTRzl4Z2pQRDUxcThDSWdXLVZaMWFBQjltTWpNNVpJaHJIcXRzYjd0WDZac0Jia3RfY1RrZHhaVEhhaUlrT2h6bTVxYlRPanRPaU83SURFZFhYXzVhZl9sX2VtdV92Z2RUb0RwcFJPaEFB?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics, Inc. Prices Public Offering of 87.5 Million Shares at $2.00 per Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPOUFmdE5ORUM0T1dINFRPWFk2TXhRUWVnXzFqYjRlTDd2Zk9pOXZNNENMUU95QjQwYXZxNnlIRG9YZUpaNFlpc1dkUUxuQUlkcF8ySExvUkFyc29XS01Cc3JkN2V4bFlFQ2ZHb1VXM0tCbVpfMmJoNW9SSURZc25ZYnAwN3F1ZnNnX3hsVkVuMURyekt0RzVCLUUwR3BDWGVXT1lqOXY2ejBORjB5aFkxOHNqcDNFNk9zc01HV3FpU2J2Z1NkYm5Ubg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Allogene Therapeutics (ALLO) Is Up 16.8% After Early ALPHA3 MRD Clearance Data And What's Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene moves to raise $175M to fund trials, R&D and operations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOcDdtcDFydmNjeDRjU29qTnAtTDduRUtDN0dZV2hYcFpBSVFuU1l2V1h5ejQxbXByZEx2RUwxek5wczdibnIyRy1pMjNFUUM0ZnJOQkJEQlFGc0FIbmwyb0tMVWplN1l5UndaZU0td0FqWjRQNzdlWHBXRWxWdnpuSEpGV0ZMRnl5RmJ1TkpZRkdMQkxUT1FhaDFnYTFjY2FBUjVlM0s2eDJxZjBlVU9QWl9PQ09hQl9wcGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxNZS1iWC00WjcySHRudWt1Z2U1N19vdlN5WnhtQ3VIUl9tZzhKMnJMTS1YaTIyTlRwS1VjNHo2TThRb0dBd2FDNy1xTkM1QlZfbTBHckpRNGRmeU5JSmpZYk5uUzY1azRMTGtmZHNBdzEzV0tocDVXZ2pfYW1tOVVCTXZuQzJKRmZQalJhU0JXVmZjaGFBZUczb3Z6SV9TcWI2LTFqV3lIZFJlSXBNMlU0bkhpOGFDZHdxX014UGIzU2RXNUR0TTRJREZLYUlVbEtvamhMamZIWmhvVDk1WnlrODRVWnYxYWtYM2xOWGhRcw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene stock sails after CAR T clears residual lymphoma in early data cut", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNaThxTU9IXzF4bS1FQ1hsZGlGdlhSUDdra1ViMG91clpzaml5UHduRGotcmxvbXE0bWJ3MUlqUmZOZWthdWx1Zllkd24xU2JNc2JLU3FCSkhaSFJseFVmNDliUkFEc3ZyV3NuR0lxdllyTDBwWThHUVJzTDdfbm93RkVfd3pndmJybVZ4VlBVTERMeDlzSUFpbnYtLUZWMlVMRVZocjZXUWw4YlBEeDhDT1EtOW5KYUk0?oc=5", "source_name": "BioSpace", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Do Analysts See 180%+ Upside for Allogene Therapeutics (ALLO)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNV01MZjF5d0VTLWg1S0Zaem5qSjZZeE81UU5lYXV1VW1qMmpXYkpGNWFsc2w4Vkw2TjRYWUtPSnM5ckcwREh6bzViSjQwODJPSGtaY1FkYURqU2NJRVUxNnJBbEdmY0M2Z2NNeGtBZEZDTEFfOUFLNHZJaVl1ZDRCMzltbzZFVmZDeVp4dDBrYjgzaXBRbVpV?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors", "summary": "Allogene Therapeutics announced the publication of complete Phase 1 data for its investigational therapy ALLO-316 in the Journal of Clinical Oncology, showing durable remissions in metastatic solid tumors. The TRAVERSE study, conducted in collaboration with The University of Texa", "url": "https://www.manilatimes.net/2026/07/15/tmt-newswire/globenewswire/allogene-therapeutics-announces-journal-of-clinical-oncology-publication-of-phase-1-results-of-allo-316-highlighting-first-durable-remissions-following-allogeneic-car-t-for-treatment-of-metastatic-solid-tumors/2385064", "source_name": "The Manila Times", "published_at": "2026-07-15T12:38:18", "published_display": "15 Jul 2026 12:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO) Q3 2024 earnings summary", "summary": "Allogene Therapeutics released its Q3 2024 earnings summary, highlighting the advancement of its key trials, including the pivotal Phase 2 ALPHA3 trial for cema-cel, with enrollment expected to complete in H1 2026. The company reported $403.4 million in cash, cash equivalents, an", "url": "https://quartr.com/events/allogene-therapeutics-allo-q3-2024_ozAJGz96", "source_name": "Quartr", "published_at": "2026-07-14T00:11:14", "published_display": "14 Jul 2026 00:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO) Proxy filing Summary", "summary": "Allogene Therapeutics (ALLO) issued a proxy filing summary on May 21, 2026, correcting total compensation figures for Dr. Chang (2024), Dr. Roberts (2025), and Mr. Parker (2025) in their Summary Compensation Table, with no other changes to the proxy statement or proposals for the", "url": "https://quartr.com/events/allogene-therapeutics-allo-proxy-filing_ozAJLWML", "source_name": "Quartr", "published_at": "2026-07-13T09:40:45", "published_display": "13 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Sinks 13%: Here\u2019s Why", "summary": "", "url": "https://finance.yahoo.com/m/57b629c0-9b57-300d-bab5-69e9c31cc364/kyverna-therapeutics-sinks.html", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T19:59:59+00:00", "published_display": "10 Jul 2026 19:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer cell therapy pioneer Allogene\u2019s new CEO is talking about a new revolution", "summary": "Zach Roberts, the new CEO of Allogene Therapeutics Inc., is advocating for a revolutionary approach to cancer cell therapy. He aims to champion new methods to address this deadly disease. The article describes Roberts' vision for the future of cancer treatment at Allogene.", "url": "https://www.bizjournals.com/sanfrancisco/news/2026/07/09/cancer-cell-therapy-lymphoma-allogene-new-ceo-lbcl.html", "source_name": "The Business Journals", "published_at": "2026-07-09T13:54:00", "published_display": "09 Jul 2026 13:54", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO) CEO granted 476,190 options and 134,530 RSUs", "summary": "Allogene Therapeutics President and CEO Zachary Roberts was granted 476,190 stock options with an exercise price of $2.11 per share and 134,530 Restricted Stock Units (RSUs). These equity awards are compensation-related and not open-market transactions. The stock options vest ove", "url": "https://www.stocktitan.net/sec-filings/ALLO/form-4-allogene-therapeutics-inc-insider-trading-activity-beb88dc09e60.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:51:49", "published_display": "06 Jul 2026 21:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPR2tMOFk1SXg4Uk9sM2VwT082eDEzRHd4TnNhN2Nsa0hXeGliQlZfQnRwTGhITnlWVjdVVEFDRHdyUFNWanVpOGExVEprQktoWXVJUVI0amVjaW9TWWZyYVp1Y3pydUhaZDZVTWhzQ3pIMnc5NkVuZk5SXzEtTkd5OEY1Q3NoRHNqTVR2YlQ0THk1T2lKaGY4ZUhZX212YmhpamNr?oc=5", "source_name": "Market source", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics: High-Upside Bet On The Next Wave Of CAR-T Innovation (NASDAQ:ALLO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQRWdjTGd2UjZkMmF1UFBxdXpPV2V3RG1sOTJGTWNMbzZyREl5Skh1QjJQWVluZWJCNi1YZmVPLTVDVm5JLVp6SkpQNS04Y1JEMWVRdi01SGVXTjBKUjVWbzJxWkZ6ZXhscDNOVmJsMUFkWFd0QzlpSGhQTkI0OVJfTjBXVGttYklzOTlFZ1Bid2J6U0ZwZy1SYUFEZ0pBNDlidXdmNWxOaHdRMktwc1lBNW96bEdoRWhE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. \u2013 NASDAQ:ALLO", "summary": "The article focuses on the enterprise value to EBITDA forward for Allogene Therapeutics, Inc. (NASDAQ:ALLO). It appears to be a stub or a data point from a financial platform like TradingView, indicating that specific financial metrics are available for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-ALLO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T07:10:13", "published_display": "28 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Allogene Therapeutics, Inc. \u2013 NASDAQ:ALLO", "summary": "This page provides financial information for Allogene Therapeutics, Inc. (NASDAQ: ALLO), focusing on its Price to Earnings Forward metric. The content highlights the company's stock market data and emphasizes that specific financial values for this metric are presented within the", "url": "https://www.tradingview.com/symbols/NASDAQ-ALLO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:09:47", "published_display": "27 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Allogene Therapeutics, Inc. \u2013 BOATS:ALLO", "summary": "This article provides financial information for Allogene Therapeutics, Inc. (ALLO), specifically focusing on its enterprise value to revenue forward. The data is presented within the context of the Blue Ocean Alternative Trade System (BOATS) on the TradingView platform.", "url": "https://www.tradingview.com/symbols/BOATS-ALLO/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:09:47", "published_display": "27 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Allogene Therapeutics, Inc. \u2013 BOATS:ALLO", "summary": "This article provides the \"Price to sales forward\" metric for Allogene Therapeutics, Inc. (ALLO), listed on the Blue Ocean Alternative Trade System (BOATS). It notes the market is currently closed with no trades. The content is primarily a data point surrounded by navigation and ", "url": "https://www.tradingview.com/symbols/BOATS-ALLO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T13:10:50", "published_display": "27 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPRmt6OVM2UnZfM0YwTWJaSWNiWDBaRXVyZXF3ZTY5ck5OQW9fcFhTOEY3YUVuNzY4LVNtS19DZzA5LW1yblMzdVNEc29YZUpsRnFPQXQtczZkYnZYTm1vbW1LelRJdzlJc3hqbWRHM0NpQS1WOExRNlpDQld3ME1JVEROZzJaX0I2Sm5kdEprZjM5ZVJBMHNZWVF3M0ZCWXJxYTJpcg?oc=5", "source_name": "Market source", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene (ALLO) director Owen Witte awarded 95,400 RSUs with deferred delivery", "summary": "Allogene Therapeutics director Owen N. Witte was granted 95,400 Restricted Stock Units (RSUs), which vest in two equal semi-annual installments over one year. Witte has elected to defer the receipt of the underlying common stock until 30 days after his continuous service terminat", "url": "https://www.stocktitan.net/sec-filings/ALLO/form-4-allogene-therapeutics-inc-insider-trading-activity-deefae0eba88.html", "source_name": "Stock Titan", "published_at": "2026-06-26T11:12:25", "published_display": "26 Jun 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLO)", "summary": "This article provides an overview of Allogene Therapeutics, Inc. (NASDAQ: ALLO) financials, stock performance, and analyst forecasts. It includes key figures such as the current stock price, market capitalization, earnings per share, and revenue, alongside analysts' high and low ", "url": "https://www.tradingview.com/symbols/NASDAQ-ALLO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:35", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALLO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Allogene Therapeutics, Inc. (ALLO) stock analysis, including its current price, analyst price targets, and future predictions. It details the company's financial performance, market capitalization, earnings reports, and employee count, alongsi", "url": "https://www.tradingview.com/symbols/NASDAQ-ALLO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:09:31", "published_display": "25 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recent pharma exec shake-ups signal strategic shifts", "summary": "Recent executive movements at major pharmaceutical companies like Novo Nordisk, Genentech, and Allogene reflect strategic adjustments within the industry. Novo Nordisk saw a significant M&A executive depart, while Genentech underwent leadership layoffs due to pipeline restructuri", "url": "https://www.pharmavoice.com/news/pharma-executive-changes-novo-genentech-allogene/823548/", "source_name": "Pharma Voice", "published_at": "2026-06-24T13:10:15", "published_display": "24 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (NASDAQ: ALLO) grants director 95,400 RSUs", "summary": "Allogene Therapeutics director Deborah M. Messemer was granted 95,400 restricted stock units (RSUs) as reported in a Form 4 SEC filing. These RSUs, which carry no purchase price, give her the contingent right to receive 95,400 shares of Allogene common stock upon vesting. The ves", "url": "https://www.stocktitan.net/sec-filings/ALLO/form-4-allogene-therapeutics-inc-insider-trading-activity-a710413f0e9d.html", "source_name": "Stock Titan", "published_at": "2026-06-24T07:39:38", "published_display": "24 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Allogene Therapeutics Inc For: 23 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Allogene Therapeutics Inc. as of June 23. It includes the company's stock symbol ALLO and its current price performance, noting a -1.43% change. The content primarily states the filing without providing further detail", "url": "https://ca.investing.com/news/stock-market-news/form-4-allogene-therapeutics-inc-for-23-june-93CH-4704102", "source_name": "Investing.com Canada", "published_at": "2026-06-23T21:09:44", "published_display": "23 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO) director receives 95,400 RSU equity award", "summary": "Allogene Therapeutics director Vicki L. Sato was granted 95,400 Restricted Stock Units (RSUs) as part of her compensation. These RSUs will vest in two equal semi-annual installments over one year, contingent on her continued service. The filing, a Form 4, indicates this is an equ", "url": "https://www.stocktitan.net/sec-filings/ALLO/form-4-allogene-therapeutics-inc-insider-trading-activity-85fe8c84bccc.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:10:15", "published_display": "23 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO) director receives 144,400 stock options grant", "summary": "Allogene Therapeutics director Stephen Mayo was granted 144,400 stock options with an exercise price of $2.00 per share. These options vest in 12 equal monthly installments and expire on June 18, 2036. Following this grant, Mayo holds options for 144,400 shares of Allogene common", "url": "https://www.stocktitan.net/sec-filings/ALLO/form-4-allogene-therapeutics-inc-insider-trading-activity-1580c42003f8.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:09:44", "published_display": "23 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene (ALLO) director awarded 95,400 RSUs with deferred share delivery", "summary": "Allogene Therapeutics, Inc. (ALLO) director Elizabeth A. Barrett was granted 95,400 Restricted Stock Units (RSUs) as part of her compensation. These RSUs will vest in two semi-annual installments over one year, contingent on her continued service. Barrett has opted to defer the d", "url": "https://www.stocktitan.net/sec-filings/ALLO/form-4-allogene-therapeutics-inc-insider-trading-activity-d570cccbe8bd.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:09:44", "published_display": "23 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (NASDAQ: ALLO) doubles authorized shares and files $135M ATM plan", "summary": "Allogene Therapeutics (NASDAQ: ALLO) announced that its stockholders approved an increase in authorized common shares from 400 million to 800 million at the 2026 Annual Meeting. This change, effective June 18, 2026, provides the company with greater flexibility for future equity ", "url": "https://www.stocktitan.net/sec-filings/ALLO/8-k-allogene-therapeutics-inc-reports-material-event-46bcdc550f33.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:40:13", "published_display": "22 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Allogene Therapeutics Inc For: 22 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPSkV2bVBsVDJVaUZtX1BNTUpLNExtNFV1UlFxcDJyVlBFalpMalpOSG02SHhkVzZwUkxTWHpsQVExZFRZVmY4TmJBdkZCYjBwVGxVdC1rQzZJUHI2WTI1SEhPQW81anBmNEl0Z0NOVjQ0QzNld29rUnM3YlVpTXZLdk9sX1JUMW1tS1c5WmQ1YWl3MFR3UlN5T0YzMTFxT0x3NVE1UWMtb1h5d3c4UGc?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALLO: All proposals, including director elections and share increase, were approved without contest", "summary": "Allogene Therapeutics, Inc. (ALLO) held its 2026 AGM where all five key proposals were approved unanimously. These proposals included director elections, executive compensation, annual advisory votes, an increase in authorized shares, and auditor ratification. No questions were r", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3620571:0-allo-all-proposals-including-director-elections-and-share-increase-were-approved-without-contest/", "source_name": "TradingView", "published_at": "2026-06-18T15:40:54", "published_display": "18 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics Inc (ALLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Allogene Therapeutics Inc (ALLO), including business segments, regional revenue, and profit contribution. However, the core information indicates that the relevant financial data has not yet been disclosed b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-allo/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T18:39:02", "published_display": "17 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNUUE4T1NFN2F6QS1FYmRDbl9YSWNYUU9jby1scGVKWHB6STVKNm1vakZ4RFRGZWxldGR0eGtKSVlaeURUZWZzZDVhMnpGM1NBNThrSU80WVR4UzBTNFl3WTdkLVRNcHhoQkt0TDRQUUg5UENEeFRPVEhGVlpDRzVhNDFlSnAxU0xHeGtWNlpQcUU5TjYzTWJDZlY4LVIxS2RscTdB?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Small Cap Stocks with Potential to Rise 1000 Percent", "summary": "This article highlights small-cap stocks with significant growth potential, focusing on Allogene Therapeutics, Inc. (NASDAQ:ALLO) as a key example. Allogene is a clinical-stage biotechnology company developing CAR T cell therapies for cancer and autoimmune diseases, with importan", "url": "https://www.insidermonkey.com/blog/10-small-cap-stocks-with-potential-to-rise-1000-percent-1782072/3/", "source_name": "Insider Monkey", "published_at": "2026-06-16T14:09:19", "published_display": "16 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPTjI2VXQ0ZG0yNGQ5RW02R0tiWjJLaE1NWWFBdTd4NUdSSm9fNXN2ZEh2WUZYRTF4eFdNVzh5U0doal9zYXQ3REtqSkFuSE5mbjEtUDI4Z2tDWlI2cTdwZExLVGY0TXZrNnFoMGdzUzhYUjBRVE83Ny1zdDRlYmdHdENaVDlfX1d3aGExb3BhU1Buc1IwVlpXTE1OakEyVHhlQmh3RFoxbw?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAR T-Cell Therapy for Non-Hodgkin\u2019s lymphoma Market Emerging as a High-Growth Healthcare Investment Space Through 2036 \u2013 DelveInsight | Gilead Sciences, Kite Pharma, Novartis, BMS, Allogene Therapeut", "summary": "DelveInsight projects the CAR T-Cell Therapy for Non-Hodgkin\u2019s lymphoma market to be a high-growth healthcare investment space through 2036, driven by rising NHL prevalence and advancements in CAR T-cell therapies. The report highlights key companies like Gilead Sciences, Novarti", "url": "https://www.barchart.com/story/news/2432722/car-t-cell-therapy-for-non-hodgkins-lymphoma-market-emerging-as-a-high-growth-healthcare-investment-space-through-2036-delveinsight-gilead-sciences-kite-pharma-novartis-bms-allogene-therapeut", "source_name": "Barchart.com", "published_at": "2026-06-12T01:09:42", "published_display": "12 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio", "summary": "Allogene Therapeutics (ALLO) is highlighted as a top penny stock due to its robust CAR T-cell therapy pipeline, including positive interim results for cema-cel in the ALPHA3 trial and development of ALLO-329 for autoimmune disease. The company reported a net loss of $42.6 million", "url": "https://www.insidermonkey.com/blog/allogene-therapeutics-inc-allo-a-top-penny-stock-to-buy-on-robust-car-t-cell-portfolio-1776523/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-07T13:57:00", "published_display": "07 Jun 2026 13:57", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALLO Stock Hits 2-Year Highs \u2013 Analyst Calls Allogene\u2019s Phase 2 Trial Data To Treat Lymphoma A \u2018Home Run\u2019", "summary": "Allogene Therapeutics (ALLO) shares surged over 50% to a two-year high after interim Phase 2 trial data for Cema-Cel in treating lymphoma showed significant efficacy. The data revealed 58.3% of treated patients had no detectable disease and a 97.7% drop in cancer DNA levels, lead", "url": "https://stocktwits.com/news-articles/markets/equity/allo-stock-2year-high-biggest-intraday-gain-cancer-treatment-data/cZJ8G6sRIuK", "source_name": "Stocktwits", "published_at": "2026-06-06T22:10:09", "published_display": "06 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A pioneering founder is stepping down as CEO of his Bay Area company ahead of a major test", "summary": "David Chang, co-founder of Allogene Therapeutics Inc., is stepping down as CEO at the end of June. This leadership change occurs as the company is conducting a critical clinical trial for a potential regulatory approval of its lymphoma treatment. The San Francisco Business Times ", "url": "https://www.bizjournals.com/sanfrancisco/news/2026/06/01/cancer-lbcl-mrd-allogene-ceo-david-chang.html", "source_name": "The Business Journals", "published_at": "2026-06-01T20:40:21", "published_display": "01 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics Names Zachary Roberts as New CEO", "summary": "Allogene Therapeutics has appointed Zachary Roberts as its new President and CEO, effective July 1, 2026, succeeding co-founder David Chang. Roberts, currently EVP of R&D and Chief Medical Officer, will also join the board, bringing extensive oncology and cell therapy experience ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ALLO/pressreleases/2209878/allogene-therapeutics-names-zachary-roberts-as-new-ceo/", "source_name": "The Globe and Mail", "published_at": "2026-05-30T20:39:45", "published_display": "30 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Common Stock of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026.", "summary": "Allogene Therapeutics, Inc. has common stock subject to a lock-up agreement that ends on May 30, 2026. The lock-up period began on April 14, 2026, and prevents the company's directors and executive officers from disposing of or hedging common stock or related securities for 45 da", "url": "https://www.marketscreener.com/news/certain-common-stock-of-allogene-therapeutics-inc-are-subject-to-a-lock-up-agreement-ending-on-30-ce7f5dd8d98df223", "source_name": "www.marketscreener.com", "published_at": "2026-05-30T18:39:53", "published_display": "30 May 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics CEO David Chang Steps Down", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/allogene-therapeutics-ceo-david-chang-211802481.html", "source_name": "MT Newswires", "published_at": "2026-05-28T21:18:02+00:00", "published_display": "28 May 2026 21:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics Announces Planned CEO Succession", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/allogene-therapeutics-announces-planned-ceo-210200905.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T21:02:00+00:00", "published_display": "28 May 2026 21:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Allogene Therapeutics beats EPS expectations in Q1 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQMDJsTDU3c2l4ajR5SzNHWTY4NU9KdFE1OEpfSTlhaERBRmVmcWtJODFFZUtVNVoyYmVfS1lTVkI4SWlpTzlNN0pMWFpwRUJDa2ZGRl84SnpEM0tjYzRsXzNpOUo1Um9Ybm82ZFBtb2NZYVhiQkp5bmJYb3dfRkZGQTlnNHhXcnBBR2c4bmo5b002RE5VN1pZTUVFY0dUVzBNclBnd2FRNWtQUW1XaTVkblpOc0JzblBDVVZoSHZPb0JDS3hYVGZuTUUtQzh0V2R6TlE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxQNUtzQ1Y1TlZsMmtMY3NFUTN1Unh5U18xNWpYaEVhdDM4OUJibUZxQ0hjWWxTb0ZMVVVIZnRQaDRRN1d4UEhzekR5SGJLRjdNT2hXVFExdXFlRElCMEFwZnZoWFpqQVdDTXJ0bG5ZVzNmX09RaU4xUWpOVFc2VEV6Nl8yQ2pJb1hpdzEzbWt3VlRkN2JiWXFRSmFKX1JWZktOa3Z6YU05czNEaFppai1pcXNWdFhrRkxxbXpTZXdSbGt4M1kzOF9wTk1tY2lGMm5yNFB2U0xIalNvcmJleTBFWlFnM1Q5c2hzaE9HMGpYbw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (NASDAQ: ALLO) Belldegrun reports 13.47M-share stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPRjcxS09laXJiamZPYVNCaGlSZGE0UnZpdXJ3T25HbXY2a24tQXIwcG1IRkphYjhtNlRXbW9fanN4S29BUWZSem5vcGxaZXhiVVlvOW5mNzVnR1Z1YWxjSEdPMktWZjlBaGJiTzk4VVNmMVJ2amxmUlJSaXhRZVZRUjNOckVWLUw5UVRpc0Nhb3VzNFBpQ0RIZUZ4VXhzYWcycUtOam1NS2lLZlpjdXdBVElvLTFvNVdWQm9vZXFXTVBqTXNERVNJZTBNdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQQVlXblBSWWRuLTQwaEQxQ1cwUGRMTy1FYVBoMVNDN3Y2WU1XeDZoSWRtbk9qX2JaTDlIdnExcjVfUmdfbkxaU1NoaXFUSUJQNFJkQm5HTDZYbmk5MkhJTGpZb2xQbEFsdDktTDhwYllmTnY4TEdIRUtWRzZTYkEzb3lIUklxTjR0c1FmMC1aaF9xdVhSTE8wdnNZeGZEZHZaTUQxNGhLUWtPUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQeXNCNG1tM3BnMkd6NWIwQTJ1M0x6ZjJZbUpXY09tdWhUWUFWbUtjbVRxQjRsNDVMeW5xRkM5bjlhT3gwR0s3NGx6Tk01RkE2Vm4zMlB1cXcwTzJEV0VTQUNWdnFMOVE3RGZQMHNOY3hUcVBmLXVsOURHcm8ybHJaQ2N3T3QtSHdxTF94X1Z6WUYyREQ5N3FtZGFuMGRIMHpneHBKVy1B?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lymphoma trial expands to 80 sites as Allogene adds 2 countries", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPS1Jhb3VxLWVPTm83V2xQS01jY3hMbnlCck05eTJ5dmQxOUZzcUVvX05aem56X0xTZm1wblVUSDdDdmRRenFjcnFKb2EwNklwaXpablhHY1FHLW1iWVpHaGhBaV9ybjg0YkRZa1BPbHNsY0tHYThtT2xVSngwc0hkYjRTRGYybDVRRU9iOV83TnI1SlNZWmhMbzNGYUxiSVM2MkxOSEhOSU9POF9UbG9OdTgxekhDNUUyQlEyMkI2NA?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene expands lymphoma trial to South Korea, Australia", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNd3VYZktRdDRhZWZJTVlsdTVZdlY2OEgyMDNjbndmbm1qUDRYdHhpZnc5aUNSTElBU0c0c1h0bnJjWXpzZ2hQdmtXaEQ1QzNkNDFBVVZKMG0wUnI1U09fdDAwbFdvaURmX0tNclduc0FQek43NmJoQnBPUzhLTEd6LVJuWjRRSThwVmFnNlFvY3ltbmtqVGRzNTBsTWZQWUhLTVZncGM4UFpZZTIzZ2ZDZ2tfZw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene sold 100.2M shares at $2, bringing in $200.4M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPS21HWEx3WEVtT2stckhaMjJtZVQ0UjNpbktENExpMEJjdXZTbEhndFlIaXVwUERaWnYxdm9LR3dZQXQwcTRoU1pLamw0TEdjRmhIdWVaT2FvMVZaVWtFWGhuQ2xITjdLUThzUzFzc3AyT1AySWdpYk1lWk5qREtvX0hiVENnNl9aMXdGNEx4SFhuaGZyYU1fVVZ3MlFPRUtCelpDWERiRGRPaS1WNWFUZE44dVZ3bTFabWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQRk4xLWxBMFJXWVN2ZTI2QnFXd1k1OTQ5aHFZajU1bEtId2N1YlNHbEs0MzlDVTVPdFBzWmUtWmtPNGw5VHJSakFBUTlQUnV0OW5Vc0k1dC14ZS1yV0pyclE5R1hoRk9yT1JMMlR2d0NiS3FBaHdUREVScWh3d3FWaGtWYWFRMlpneEdYWVBnSjBqeGFqVzJoNzdxQjZfOVFFNzAzdDVfazVXSFBVRE1mQUdB?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNWkR0cnp2X1RqTGViaU9TbnVEbW0yS3BfdkdYWVJlLXpneFA0QnJUZGptaDI0UU1keW02YXBTRzl4Z2pQRDUxcThDSWdXLVZaMWFBQjltTWpNNVpJaHJIcXRzYjd0WDZac0Jia3RfY1RrZHhaVEhhaUlrT2h6bTVxYlRPanRPaU83SURFZFhYXzVhZl9sX2VtdV92Z2RUb0RwcFJPaEFB?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics, Inc. Prices Public Offering of 87.5 Million Shares at $2.00 per Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPOUFmdE5ORUM0T1dINFRPWFk2TXhRUWVnXzFqYjRlTDd2Zk9pOXZNNENMUU95QjQwYXZxNnlIRG9YZUpaNFlpc1dkUUxuQUlkcF8ySExvUkFyc29XS01Cc3JkN2V4bFlFQ2ZHb1VXM0tCbVpfMmJoNW9SSURZc25ZYnAwN3F1ZnNnX3hsVkVuMURyekt0RzVCLUUwR3BDWGVXT1lqOXY2ejBORjB5aFkxOHNqcDNFNk9zc01HV3FpU2J2Z1NkYm5Ubg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Allogene Therapeutics (ALLO) Is Up 16.8% After Early ALPHA3 MRD Clearance Data And What's Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene moves to raise $175M to fund trials, R&D and operations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOcDdtcDFydmNjeDRjU29qTnAtTDduRUtDN0dZV2hYcFpBSVFuU1l2V1h5ejQxbXByZEx2RUwxek5wczdibnIyRy1pMjNFUUM0ZnJOQkJEQlFGc0FIbmwyb0tMVWplN1l5UndaZU0td0FqWjRQNzdlWHBXRWxWdnpuSEpGV0ZMRnl5RmJ1TkpZRkdMQkxUT1FhaDFnYTFjY2FBUjVlM0s2eDJxZjBlVU9QWl9PQ09hQl9wcGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxNZS1iWC00WjcySHRudWt1Z2U1N19vdlN5WnhtQ3VIUl9tZzhKMnJMTS1YaTIyTlRwS1VjNHo2TThRb0dBd2FDNy1xTkM1QlZfbTBHckpRNGRmeU5JSmpZYk5uUzY1azRMTGtmZHNBdzEzV0tocDVXZ2pfYW1tOVVCTXZuQzJKRmZQalJhU0JXVmZjaGFBZUczb3Z6SV9TcWI2LTFqV3lIZFJlSXBNMlU0bkhpOGFDZHdxX014UGIzU2RXNUR0TTRJREZLYUlVbEtvamhMamZIWmhvVDk1WnlrODRVWnYxYWtYM2xOWGhRcw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Allogene stock sails after CAR T clears residual lymphoma in early data cut", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNaThxTU9IXzF4bS1FQ1hsZGlGdlhSUDdra1ViMG91clpzaml5UHduRGotcmxvbXE0bWJ3MUlqUmZOZWthdWx1Zllkd24xU2JNc2JLU3FCSkhaSFJseFVmNDliUkFEc3ZyV3NuR0lxdllyTDBwWThHUVJzTDdfbm93RkVfd3pndmJybVZ4VlBVTERMeDlzSUFpbnYtLUZWMlVMRVZocjZXUWw4YlBEeDhDT1EtOW5KYUk0?oc=5", "source_name": "BioSpace", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Do Analysts See 180%+ Upside for Allogene Therapeutics (ALLO)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNV01MZjF5d0VTLWg1S0Zaem5qSjZZeE81UU5lYXV1VW1qMmpXYkpGNWFsc2w4Vkw2TjRYWUtPSnM5ckcwREh6bzViSjQwODJPSGtaY1FkYURqU2NJRVUxNnJBbEdmY0M2Z2NNeGtBZEZDTEFfOUFLNHZJaVl1ZDRCMzltbzZFVmZDeVp4dDBrYjgzaXBRbVpV?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 104, "total_relevant": 64, "sentiment_summary": {"positive": 19, "negative": 2, "neutral": 43, "score": 56, "total": 64, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 22.35, "count": 40}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 2.0, "latest_week": "2026-07-10", "one_week_move": -3.8, "four_week_move": 5.3, "twelve_week_move": -16.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.723421, "market_dynamics_buy_signal": false, "relative_strength": 1.949818, "fair_value_gap": -16.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 46.2927, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.8% over one week, +5.3% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Stock Titan", "count": 11}, {"label": "TradingView", "count": 7}, {"label": "GlobeNewswire", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Quartr", "count": 2}, {"label": "The Business Journals", "count": 2}, {"label": "Investing.com Canada", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 40}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.8% over one week, +5.3% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors"}], "updated_at": "2026-07-16T12:57:03.613811+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}